ReviewPharmaceuticals (Basel, Switzerland)2016
TRPV1: A Target for Rational Drug Design.
Review in Pharmaceuticals (Basel, Switzerland), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 110 citations in OpenAlex.
- Capsaicin for Orofacial Pain Management: Systematic Review and Meta-Analysis.International journal of molecular sciences · 2026Pooled it
- Review
- TRPV1 manipulating polarization of M1/M2 macrophages to promote skeletal muscle regeneration.Skeletal muscle · 2026Article
- Insights into ion channels to identify drug target for neuropathic pain management.Inflammopharmacology · 2025Review
- Neurotoxins Acting on TRPV1-Building a Molecular Template for the Study of Pain and Thermal Dysfunctions.Toxins · 2025Review
- TRPV1-target drugs for the treatment of orofacial pain.Frontiers in pharmacology · 2025Review
- Targeting Perineural Invasion in Pancreatic Cancer.Cancers · 2024Review
- Article
- Article
- Dissecting the contributions of membrane affinity and bivalency of the spider venom protein DkTx to its sustained mode of TRPV1 activation.The Journal of biological chemistry · 2023Article
- Natural Active Ingredients and TRPV1 Modulation: Focus on Key Chemical Moieties Involved in Ligand-Target Interaction.Plants (Basel, Switzerland) · 2023Review
- A bibliometrics analysis and visualization study of TRPV1 channel.Frontiers in pharmacology · 2023Review
- A new era for the design of TRPV1 antagonists and agonists with the use of structural information and molecular docking of capsaicin-like compounds.Journal of enzyme inhibition and medicinal chemistry · 2022Article
- A Potential Route of Capsaicin to Its Binding Site in the TRPV1 Ion Channel.Journal of chemical information and modeling · 2022Article
- Venom Peptide Toxins Targeting the Outer Pore Region of Transient Receptor Potential Vanilloid 1 in Pain: Implications for Analgesic Drug Development.International journal of molecular sciences · 2022Review
- Article
- Resiniferatoxin Hampers the Nocifensive Response of Caenorhabditis elegans to Noxious Heat, and Pathway Analysis Revealed that the Wnt Signaling Pathway is Involved.Neurochemical research · 2022Article
- Relationship between acupuncture and transient receptor potential vanilloid: Current and future directions.Frontiers in molecular neuroscience · 2022Review
- TRPV1 channels as a newly identified target for vitamin D.Channels (Austin, Tex.) · 2021Review
- Computational Modeling to Explain Why 5,5-Diarylpentadienamides are TRPV1 Antagonists.Molecules (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Transient Receptor Potential Vanilloid 1 (TRPV1) is a non-selective, Ca(2+) permeable cation channel activated by noxious heat, and chemical ligands, such as capsaicin and resiniferatoxin (RTX). Many compounds have been developed that either activate or inhibit TRPV1, but none of them are in routine clinical practice. This review will discuss the rationale for antagonists and agonists of TRPV1 for pain relief and other conditions, and strategies to develop new, better drugs to target this ion channel, using the newly available high-resolution structures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.